New Type 2 Diabetes Treatment Shows Promise in First Human S
Patients with type 2 diabetes who received daily treatment with sodium phenylbutyrate for 2 weeks had significant improvements in peripheral insulin sensitivity and glucose oxidation.

The treatment appeared safe, with no reported adverse events.

The results show, for the first time in humans, that treatment with an agent that cuts levels of branched-chain amino acids by boosting their breakdown produces substantial beneficial effects on glucose metabolism in patients with type 2 diabetes.

The findings are proof-of-concept that treatments that target branched-chain amino acids may be a new management strategy for patients with type 2 diabetes.

A single-center, randomized, double-blind, placebo-controlled, crossover study with 18 enrolled patients and 16 patients with evaluable results who were included in the analysis.

Patients were an average of 66 years old and had been diagnosed with type 2 diabetes for an average of 1.5 years.

On top of their background glucose-lowering medications, participants received 4.8 g/m2/day sodium phenylbutyrate or placebo divided into three doses per day for 2 weeks, followed by a 6-8 week washout period, and then 2 weeks on the alternative treatment.

The primary outcome was change from baseline in peripheral insulin sensitivity, measured by the insulin-stimulated glucose disposal rate.

Peripheral insulin sensitivity improved after 2 weeks on sodium phenylbutyrate by a significant 27% compared with placebo (P = .0155).

Sodium phenylbutyrate also significantly improved several secondary measures compared with placebo including carbohydrate-driven muscle mitochondrial oxidative capacity, whole-body insulin-stimulated carbohydrate oxidation, and reduced plasma levels of branched-chain fatty acids.

1 share